Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sdz asm 981.

K Wellington1, C M Spencer

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|November 24, 2007
PubMed
Summary
This summary is machine-generated.

SDZ ASM 981, a novel macrolactam, shows anti-inflammatory effects by inhibiting cytokine synthesis. Topical and oral formulations demonstrated efficacy in treating atopic dermatitis and psoriasis, with good tolerability and no systemic adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

CNS drugs·2016
Same author

Quetiapine : A Review of its Use in Schizophrenia.

CNS drugs·2016
Same author

The Yin and Yang of inflammation.

Current molecular medicine·2014
Same author

Lymphotoxin beta receptor signaling limits mucosal damage through driving IL-23 production by epithelial cells.

Mucosal immunology·2014
Same author

Lanoteplase.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Levosalbutamol.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • SDZ ASM 981 is a macrolactam with anti-inflammatory properties.
  • It functions by inhibiting calcineurin and subsequent inflammatory cytokine synthesis.
  • Macrophilin-12 is a high-affinity binding target for SDZ ASM 981.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of SDZ ASM 981 in treating inflammatory skin conditions.
  • To assess the dose-dependency of SDZ ASM 981 in various patient populations.
  • To compare the efficacy of SDZ ASM 981 with existing treatments like betamethasone valerate and clobetasol.

Main Methods:

  • Clinical trials involving adult and pediatric patients with atopic dermatitis.
  • Studies on patients with chronic psoriasis and allergic contact dermatitis.

Related Experiment Videos

  • Administration of topical and oral formulations of SDZ ASM 981 at varying doses.

    • Main Results:

    • Topical SDZ ASM 981 1% cream showed efficacy in atopic dermatitis but was less effective than betamethasone valerate 1% cream.
    • Efficacy of topical SDZ ASM 981 was dose-dependent.
    • Oral SDZ ASM 981 demonstrated dose-dependent efficacy in reducing psoriasis severity without adverse effects.
    • Topical and oral treatments showed good tolerability, with no systemic adverse reactions or atrophogenic potential.

    Conclusions:

    • SDZ ASM 981 is an effective anti-inflammatory agent for dermatological conditions.
    • It offers a favorable safety profile, lacking the atrophogenic potential of corticosteroids.
    • Further research may explore its therapeutic potential in inflammatory skin diseases.